Since PI3K pathway mutations are now known to cause intractable epilepsy, repurposing pathway-targeted anti-cancer drugs offers a tantalizing opportunity to fundamentally shift the therapeutic approach toward intractable epilepsy. This evidence concerns the gene PIK3CA and cancer.